These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9835508)

  • 1. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.
    Srinivas RV; Middlemas D; Flynn P; Fridland A
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3157-62. PubMed ID: 9835508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
    Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
    AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.
    Dupuis ML; Tombesi M; Sabatini M; Cianfriglia M
    Chemotherapy; 2003 May; 49(1-2):8-16. PubMed ID: 12714803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
    Jones K; Hoggard PG; Sales SD; Khoo S; Davey R; Back DJ
    AIDS; 2001 Apr; 15(6):675-81. PubMed ID: 11371681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
    Lucia MB; Anu R; Handley M; Gillet JP; Wu CP; De Donatis GM; Cauda R; Gottesman MM
    Br J Cancer; 2011 Aug; 105(4):513-22. PubMed ID: 21829205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.
    Bierman WF; Scheffer GL; Schoonderwoerd A; Jansen G; van Agtmael MA; Danner SA; Scheper RJ
    J Antimicrob Chemother; 2010 Aug; 65(8):1672-80. PubMed ID: 20551216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
    Fukuda Y; Takenaka K; Sparreboom A; Cheepala SB; Wu CP; Ekins S; Ambudkar SV; Schuetz JD
    Mol Pharmacol; 2013 Sep; 84(3):361-71. PubMed ID: 23775562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
    Sampson A; Peterson BG; Tan KW; Iram SH
    Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
    Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
    Zhang L; Gorset W; Washington CB; Blaschke TF; Kroetz DL; Giacomini KM
    Drug Metab Dispos; 2000 Mar; 28(3):329-34. PubMed ID: 10681378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line.
    Maffeo A; Bellomi F; Solimeo I; Bambacioni F; Scagnolari C; De Pisa F; Dupuis ML; Cianfriglia M; Antonelli G; Turriziani O
    New Microbiol; 2004 Apr; 27(2 Suppl 1):119-26. PubMed ID: 15646074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
    Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
    Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
    Rothweiler F; Michaelis M; Brauer P; Otte J; Weber K; Fehse B; Doerr HW; Wiese M; Kreuter J; Al-Abed Y; Nicoletti F; Cinatl J
    Neoplasia; 2010 Dec; 12(12):1023-30. PubMed ID: 21170266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
    Dupuis ML; Flego M; Molinari A; Cianfriglia M
    HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
    Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
    Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
    Gupta A; Zhang Y; Unadkat JD; Mao Q
    J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
    van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
    AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
    Lucia MB; Rutella S; Leone G; Vella S; Cauda R
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.